No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TBIO TELESIS BIO
- 0.318
- -0.003-0.93%
Close Apr 26 16:00 ET
- 0.325
- +0.007+2.14%
Post 19:03 ET
9.58MMarket Cap-194P/E (TTM)
0.318High0.308Low26.54KVolume0.317Open0.321Pre Close8.33KTurnover0.29%Turnover RatioLossP/E (Static)30.10MShares3.01052wk High39.80P/B2.90MFloat Cap0.30052wk Low--Dividend TTM9.10MShs Float25.700Historical High--Div YieldTTM3.30%Amplitude0.300Historical Low0.313Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) shares rose 51.8% to $1.29 during Thursday's after-market session. The company's market cap stands at $212.3 million. Fresh2 Group (NASDAQ:FRES) stock rose 10
Telesis Bio Leadership Shake-Up and Board Expansion
Express News | Telesis Bio Inc - on April 16 Board Approved Expansion of Board From Seven to Eight Members
Express News | Telesis Bio Inc - Eric Esser, President and COO of Telesis Bio, Will Assume Role of Company's CEO and Will Join Company's Board
Express News | Telesis Bio Inc - Todd R. Nelson Ph.d., Founder and CEO of Telesis Bio Will No Longer Be Company's CEO and Will Transition to a Board-Only Role
Express News | Telesis Bio Inc. Announces Strategic Focus on Game-Changing Gibson Sola Enzymatic DNA Synthesis (Eds) Platform and Bioxp Mrna Solutions and Announces New Leadership
Comments
$TELESIS BIO(TBIO.US$
NEWS
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
Telesis Bio focuses on Gibson SOLA and BioXp platforms for DNA and mRNA synthesis
Collaborations aim to accelerate drug discovery with rapid vaccine and therapeutic candidate identification
Operational restructuring leads to significant cost savings and extends cash runway
NEWS
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
Telesis Bio focuses on Gibson SOLA and BioXp platforms for DNA and mRNA synthesis
Collaborations aim to accelerate drug discovery with rapid vaccine and therapeutic candidate identification
Operational restructuring leads to significant cost savings and extends cash runway
🔴增持？维持？减持？
⭕上市公司的早期投资者在IPO锁定期结束后是否有减持，其在不同股价区间有多大程度的增持或减持，往往可以看作对公司有深度了解的知情者对公司前景的投票结果。
…in an IPO, there is a lock-up period—typically between 90 to 180 days—in which shareholders are restricted from selling outside of the Initial Public Offering.
⭕$TELESIS BIO(TBIO.US$ 的早期风投，内部人士以及战略投资者$Danaher(DHR.US$ 的持仓变化似乎就可以说明一些问题。
⭕对公司护城河以及护城河构建者的了解往往又可从另一个角度对公司前景有所预判。比如，$TELESIS BIO(TBIO.US$ 首席技术官 Dan Gibson 5年前的一个TED演讲，是否能增加你对公司的认知呢？——How to build synthetic DNA and send it across the internet
⭕对不同时...
…in an IPO, there is a lock-up period—typically between 90 to 180 days—in which shareholders are restricted from selling outside of the Initial Public Offering.
⭕$TELESIS BIO(TBIO.US$ 的早期风投，内部人士以及战略投资者$Danaher(DHR.US$ 的持仓变化似乎就可以说明一些问题。
⭕对公司护城河以及护城河构建者的了解往往又可从另一个角度对公司前景有所预判。比如，$TELESIS BIO(TBIO.US$ 首席技术官 Dan Gibson 5年前的一个TED演讲，是否能增加你对公司的认知呢？——How to build synthetic DNA and send it across the internet
⭕对不同时...
+3
1
$TELESIS BIO(TBIO.US$ almost breaks that high, damn
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg